Zhongzhu Healthcare Holding (600568) Stock Overview

Zhongzhu Healthcare Holding Co.,Ltd engages in the research, development, production, and sales of pharmaceuticals drugs in China. It offers ophthalmology drugs, including pearl eye drops, sodium cromoglycate eye drops solution, acyclovir eye drops, hydroxybenzazole hydrochloride eye drops, acyclovir dispersible tablets, gatifloxacin tablets, etc. It is also involved in production and sales of products, including hepatest ultrasonic liver cirrhosis detector, infusion heater, Luna God full-body gamma knife, etc. In addition, the company engages in residential real estate development, capital market services, technology promotion and application service, medical services and devices, special equipment manufacturing, software and information technology service, hospital investment management, leasing and business services. The company researches and develops drugs, such as Genistein capsule which has completed the phase 2 clinical research for the prevention and treatment of women's menopausal syndrome, osteoporosis, and anti-tumor effect; Leonurine sulfate tablets, which has completed phase 1b clinical study for the prevention and treatment of cardiovascular and cerebrovascular diseases and strokes; and motherwort. The company was formerly known as Zhongzhu Holding Co., Ltd. and changed its name to Zhongzhu Healthcare Holding Co., Ltd in June 2016. The company was founded in 1970 and is headquartered in Zhuhai, China.